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ABSTRACT 
Objective: The present work was aimed to prepare niosomes entrapping salbutamol sulphate (SS) using reversed phase evaporation method (REV). 
Methods: Niosomes were prepared by mixing span 60 and cholesterol in 1:1 molar ratio in chloroform, SS in water was then added to organic phase 
to form niosomal SS. Formulations after evaporation of chloroform, freeze centrifuged then lyophilized, were evaluated for particles size, 
polydispersity index (Pdi), zeta-potential, morphology, entrapment efficiency (EE%) and in vitro release. For pulmonary delivery; metered dose 
inhalers (MDI) were prepared by suspending SS niosomes equivalent to 20 mg SS in hydrofluoroalkane (HFA). The metered valve was investigated 
for leakage rate, the total number of puffs/canister, weight/puff, dose uniformity and particle size.  
Results: The results showed spherical niosomes with 400-451 nm particles that entrapped 66.19% of SS. 76.54±0.132% SS release from niosomes 
that showed a controlled release profile for 8h. The leakage test was not exceeding 4 mg/3 d, the number of puffs were up to 200puffs/canister, the 
dose delivered/puff was 0.1 mg and 0.64-4.51μm niosomal aerosol.  
Conclusion: The results indicate an encouraging strategy to formulate a controlled drug delivery by entrapping (SS) in niosomes which could be 
packaged into (MDI) that met the requirements of (USP) aerosols guidelines which offering a novel approach to respiratory delivery. 
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The pulmonary delivery route is characterized with rapid onset, 
non-invasive nature and lack of proteolytic enzymes in lungs 
compared to gastrointestinal tract. In addition, onset is more rapid 
in case of localized delivery to lungs by inhaled medications [1-3]. 
Metered dose inhalers (MDIs) effectively made asthma medications 
simple for patients to administer to themselves. The combination of 
the large dispersion area of both aerosolized drug delivery systems 
and lungs synergistically facilitate the rapid uptake of the drug into 
systemic circulation offering a controlled method to deliver a known 
therapeutic amount with each dose [4-5]. Niosome is one of the most 
promising nano-carriers that can be used in targeted drug delivery 
systems in a controlled manner [6] showing bioavailability 
enhancement, continuous therapeutic effect over a longer period of 
time, preventing the excess drug from pouring into the systemic 
circulation, protecting drugs from degradation in vivo and therefore, 
results in reduced side-effects [7-8]. 
Salbutamol sulphate (SS) was developed and indicated for the 
symptomatic relief and prevention of bronchospasm due to 
bronchial asthma, chronic bronchitis and other chronic Broncho 
pulmonary disorders in which bronchospasm is a complicating 
factor. In addition, it prevents exercise-induced bronchospasm. SS is 
subjected to the first-pass metabolism and rapidly absorbed from 
the gastrointestinal tract when taken orally [9]. SS is a good 
candidate for controlled release formulations since its short half-life 
(2-4 h) that necessitates frequent administration to maintain 
constant therapeutic drug levels, in addition to its high water 
solubility [10]. Also, Anti-asthmatic drugs have high potential to 
induce toxic side effects after parenteral administration; stimulation 
of beta receptors, occur in the body. This effect results in cardiac 
stimulation by receptors and peripheral vasodilatation and 
hypotension [11]. The aforementioned facts directed our interest to 
design a new nano-based SS MDI according to the USP guidelines to 
reduce the uptake of SS by β1 
MATERIALS AND METHODS 
receptors and to deliver the drug in a 
controlled manner which reduces the recurrent doses and 
consequently reduces its toxic effect.  
Experimental 
Materials and reagents 
Salbutamol sulphate (99.90%), propellant HFA and soya leicithin 
were kindly supplied by The Arab Drug Co., Egypt. Cholesterol (95% 
stabilized) was purchased from Acros organics, (U. K.). Span 60 and 
chloroform were purchased from Sigma-Aldrich, Germany.  
Instruments  
Ultraviolet-visible spectrophotometer (V-630, Jasco, Japan), Digital 
precise Shaking Water Bath (WSB-18, Dahan Scientific Co. Ltd., 
Korea), Scanning electron microscope (JEOL 5500 LV., Tokyo, Japan), 
Transmission electron microscope (JEOL JSM-6510 LV., Tokyo, 
Japan), Rotary evaporator (OSB-2100, N-1200A, Shanghai Eyela Co. 
Ltd., China), Freeze centrifuge (2-16KL, Sigma Laborzentrifugen 
GmbH, Germany), (PAMASOL 2015, Switzerland) and Malvern 
Instruments Ltd (Zetasizer Nano-Zs90, MPT-Z, UK) were used.  
Preparation of niosomes 
Niosomes containing SS were prepared by reversed-phase 
evaporation method (REV) that representing formula (N). A mixture of 
Span 60 and cholesterol (1:1 molar ratio) was dissolved in chloroform. 
Subsequently, 0.5 g SS was dissolved in water then the aqueous phase 
was added to the lipid phase. The mixture was then emulsified using 
bath sonicator for 10 min at 10 °C. The emulsion was rotary-
evaporated at 40 °C with a rotating speed of 50 rpm for about 15 min 
to remove the organic solvent; Traces of chloroform were eliminated 
by employing rotary evaporator for extra 10 min. The suspension then 
was centrifuged using a refrigerated centrifuge at 4 °C, 10.000 rpm for 
1 h, lyophilized and kept at 4 °C for further investigations [12-13]. 
Characterization of niosomes 
Scanning electron microscopy (SEM) of niosomes 
Samples were sprinkled on SEM holder with double-sided adhesive 
tape, coated with a layer of 150 Å gold for two minutes by SPI 
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module TM gold sputter coater and examined using a high vacuum 
mode of SEM [14]. 
Transmission electron microscopy (TEM) of niosomes 
A 10-fold aqueous diluted drop of the niosomal dispersion was 
subjected to collodion-coated 300 mesh copper grid, left for 5 min, 
adsorbed using filter paper then a drop of 2% aqueous uranyl acetate 
was applied for 1 minute, the remaining solution was removed and the 
samples were air dried and examined at 80 KV [14]. 
Particle size, polydispersity index and zeta-potential of niosomes 
Nanoparticle size distribution, polydispersity index and zeta-
potential were determined using photon correlation spectroscopy 
(Zeta Potential Analyzer; Malvern Zetasize Nano-zs90, Malvern 
Instruments, Malvern, UK). The size distribution analysis was 
performed at a scattering angle of 90 degrees and at a temperature 
of 25 °C using samples appropriately diluted with dispersant water. 
For each sample, the mean diameter±standard deviation of 10 
determinations was calculated applying multimodal analysis [15]. 
Entrapment efficiency (EE %) of SS in niosomes 
Two mg of SS niosomes was mixed with 10 ml of absolute alcohol; 
0.1 ml of the resultant SS niosomal dispersion was diluted with 
absolute alcohol and sonicated for ten minutes to obtain a clear 
solution. The concentration of entrapped SS was determined 
spectrophotometrically at 276 nm using UV spectrophotometer 
against the sample withdrawn from empty niosomal dispersion 
treated in a similar manner. The entrapment efficiency was 
determined relative to the original drug concentration as (EE % = 
ED/TD *100, Equation 1) Where EE % is the entrapment efficiency 
percent, ED is the entrapped drug concentration and TD is the 
theoretical drug concentration [16]. 
In vitro release of SS from niosomes 
The release of SS from niosomes was determined using the 
membrane diffusion technique [17-18]. One ml phosphate buffer 
(pH 7.4) was used to suspend SS; equivalent to 10 mg. The 
suspension was transferred to a glass tube with a soaked cellulose 
membrane that enclosed its lower end. Then, the glass tube was 
placed in a beaker containing 50 ml phosphate buffer (pH 7.4) that 
was maintained at a temperature of 37◦
Preparation of MDI 
C [19]. Using shaker water 
bath; the beaker was kept under mild agitation (50 rpm). Aliquots 
were withdrawn at predetermined time intervals for 8h, then the 
drug concentration was determined at 276 nm. The experiment was 
run in triplicates. The obtained data were kinetically analyzed to 
determine the pattern of the drug release. For better 
characterization of the drug release behaviour for the systems 
studied and to understand the corresponding mechanism, 
Korsmeyer-Peppas semi-empirical model was applied [20-21]. 
Two formulae were used. MDI (F1), containing 20 mg SS (0.01% of 
the whole canister) in propellant HFA and considered the control 
batch, while MDI (F2) containing the REV SS niosomes (table 1). The 
prescribed quantity of the selected niosomes (20 mg SS) was 
suspended in the propellant HFA that was used as a solvent applying 
soya leicithin as a dispersing agent and then quantitatively placed in 
the aerosol container, the valve assembly was inserted and crimped 
into place, and pressure was introduced into the container equal to 
propellant vapor pressure from a pressure burette. When the 
pressure in the container equals that in the burette, the process was 
stopped. The desired pressure was obtained by increasing the 
pressure in the filling apparatus through the use of compressed air, 
using the typical pamasol packaging line that was used to fill the 
metered dose aerosol inhalers. 
 
Table 1: Composition of SS alone and SS niosomes for aerosol studies 
Formula Amount of ingredients in (g) Molar ratio Amount of SS in the whole canister 
SS Span60: cholesterol Span60: cholesterol (mg) (%) 
F1 0.02 - - 20 0.01 
F2 1.5 6.4:5.6 1:1 20 0.01 
Note: Niosomes in formula 2 (F2) are entrapping 20 mg SS, (SS): Salbutamol Sulphate 
 
Characterization of niosomal MDI according to US pharma-
copeia, 2004  
The particle size of niosomal aerosol was measured by laser 
diffraction Malvern Mastersizer as a suitable alternative to impaction 
methods [22]. Particle size analysis of each sample was performed 
with reference particle refractive index (1.5295, 0.1000) and reference 
dispersant refractive index (1.3300). The particle size of niosomal 
aerosol is converted into a volume based size according to a reported 
method [23]. The residual volume was 1.820%. The preparation was 
appropriately diluted with purified water inside the Malvern sample 
dispersion unit for analysis using the 300 RF lens as recommended by 
the manufacturer, and laser radiation unit class 3B with a 
measurement beam lens of 2.40 mm and a range lens of 45 mm for 
each measurement attached to a measuring cell. The obscuration level 
was kept between 40-55% at a stable count rate. The average particle 
size was determined from triplicate of each sample. 
Leakage rate was carried out using ten aerosol containers. Each 
container was weighed (W1) then allowed to stand in an upright 
position at a temperature of 25.0±2.0 C̊ for 3 d. Each container was 
weighed again (W2) then; the h (T) during which the containers 
under test were recorded. The leakage rate (mg/year) of each 
container was calculated by the formula of 365*(24/T)*(W1-W2
To calculate weight per puff, the valve of each container was actuated 
for 10 puffs, and then; each container was weighed again (W2). The 
total weight loss from each canister was calculated (W1-W2). The total 
number of puffs was determined by counting the number of priming 
discharges until the container was empty using 10 cans. 
). 
Dose uniformity was determined using a reported method [24] in 
which a collection tube covered with a tubing connector and a 
mouthpiece adaptor was tested. Using a mouthpiece adaptor 
ensured that the tip of the inhaler mouthpiece was flushed with the 
open end of the sample collection tube. Each canister had been 
shaken well, four puffs were discharged away in the air then the 
minimum recommended dose was discharged into the apparatus 
through the mouthpiece adaptor by depressing the valve four times 
allowing at least 10 seconds between doses to ensure that the dose 
has been completely discharged. The inhaler was detached from the 
apparatus; the content of the apparatus was assayed for drug 
spectrophotometrically at 276 nm after rinsing the interior of the 
apparatus with 10 ml methanol against the blank sample.  
The drug content over the entire can in each of 10 separate containers 
was also determined. The stem valve and mouthpiece were removed 
with a special device then the whole canister content was diluted with 
methanol; dose uniformity over the entire content was assayed 
spectrophotometrically at 276 nm against the blank sample. 
RESULTS AND DISCUSSION 
Characterization of niosomal vesicles 
Entrapment efficiency (EE %) 
The EE% of SS in niosomes was found to be 66.19%±0.48. This result 
was in accordance with [25] who reported that REV method is the most 
efficient method used to entrap water-soluble drug. Furthermore, [26] 
reported that REV method used to prepare Hydroxychloroquine in 
niosomes achieved the highest entrapment efficiency (86.4%). Reverse-
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phase evaporation method has these unique advantages for 
encapsulating water-soluble materials such SS as the organic solvent is 
simply removed from the inverted micelles resulting in vesicles with 
larger aqueous space to lipid ratio and consequently higher EE%.  
Particle size, polydispersity index and zeta-potantial of niosomes 
A particle size ranged from 400-450 nm (fig. 1. a) with a dispersant 
RI 1.330 and viscosity (cP) equals 0.8872 was considered optimum 
for pulmonary application. Polydispirsity index (Pdi) value was 
0.354 that indicates the homogenous distribution of formed 
niosomes (fig. 1. a). Zetapotential of RE niosomes was-46.5 which 
reflects the stability of formed niosomes (fig. 1. b), [27]. 
Scanning electron microscopy (SEM) 
SEM illustrated surface characteristics of REV SS-loaded niosomes 
(fig. 1. c) which appeared spherical with some discontinuities in the 
membrane. This may be explained as the acyl-chain structure of 
span 60 could affect cholesterol interactions causing variations in 
cholesterol distribution. The polar head group of non-ionic 
surfactant must cover the non-polar portion of cholesterol; this 
coverage is essential to avoid the unfavourable free energy of 
cholesterol that when contacts with water decrease the repulsion 
between cholesterol molecules [28]. 
Transmission electron microscopy (TEM)  
The morphology of the selected formula of REV SS-loaded niosomes 
(fig. 1. d), revealed the presence of well identified spherical multi-
lamellar vesicles existing in disperse pattern.  
Fig. 1: Particle size (a), zeta-potential (b), scanning electron 




Fig. 1: The release profile of REV niosomal SS 
 
The results illustrated in (fig. 2. a) showed that SS release percent after 
eight hours from REV SS niosomes was 76.54%±0.132. Furthermore, the 
slow release rate depends on both polymer breakdown and diffusion out 
of the matrix. Correlation of release data revealed that the release profile 
followed Higuchi model with regression parameters of rP2P =0.992, for REV 
SS niosomes (fig. 2. b). This kinetic pattern indicated that SS release is 
dominated by diffusion model which normally depends on drug 
concentration gradient between nano-vesicles and dissolution media 
with penetration of this media through a porous wall which 
accompanied by matrix disruption [29]. 
 
 
Fig. 2: (a) The release of REV SS from niosomes of span60 and cholesterol in the molar ratio 1:1 in phosphate buffer pH 7.4 at 37˚C. (b) 
Higuchi diffusion model for the release of SS from niosomal vesicles, sqrt (t): square root of time in hours, amount/S. A: amount of drug 
release per unit surface area at time t. n=3, data are expressed as mean±SD 
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In this light, release can be changed by varying system surface 
area and wettability; determined by size and uniformity. 
Meanwhile, loading percentage directly affects the drug 
concentration gradient and release rate [30]. Further kinetic 
studies were carried out and the release pattern was non fickian 
with n = 0.6929 for N (table 2). 
 
Table 2: Release kinetics of SS from different niosomal formulations 
Formula  Higuchi diffusion Korsmeyer-peppas Mechanism of drug release 
RP2 RP2 K n 
 N 0.992 0.999 0.006 0.6929 Non Fickian 
Note: formula (N): Niosomes containing salbutamol sulphate (SS) that prepared by reversed-phase evaporation method (REV), (RP2P): linear 
regression, (K): a constant incorporating characteristics of the particle system, (n): the diffusion exponent 
 
Characterization of niosomal MDI according to USP 
Characterization of niosomal MDI was performed. Statistical analysis 
using one way ANOVA (p<0.05) was carried out by graphpad 
prism6P® P showing that the results complies with pharmacopeial 
specifications according to USP 2004. Fig. (3) Illustrates the particle 
size of aerosolized REV SS niosomes which ranged from 0.64 to 4.51 
μm. The results also indicate that niosomal SS particle size measured 
by (TEM) and (SEM) were in good agreement with malvern 
mastersizer results, which was almost below 5μm. Particles larger 
than 5μm are rapidly removed from the lung by coughing or 
swallowing while particles smaller than 0.5 μm may escape 
impaction in the upper airways, thus only aerosols 3-5 μm in 
diameter show efficient penetration into the lungs [31]. All 
characterization parameters were studies according to US 
Pharmacopeia, 2004 [32]. 
The results illustrated in (table 3) showed that, weight varies from 
22.65-23.69 gm with no significant differences between the 20 cans 
(p<0.05) as (23.42±0.24) for SS and (20.65±0.33) for niosomal SS. 
Weight per puff (mg) of 10 canisters of SS and niosomal SS were found 
to be (83±0.31) and (80±0.27) mg, respectively which is not less than 
71 mg and not more than 83 mg/puff. Leakage test (mg/year) showed 
(425±1.89) for SS and (472±0.56) for niosomal SS. Number of puffs 
per canister (delivery/canister) for 10 containers showed (190±0.53) 
and (215±0.61) (del/can) for SS and niosomal SS respectively. 
Regarding dose uniformity per puff, the results showed (115%±0.19) 
for SS and (95%±0.55) for niosomal SS, this in accordance with the 
recorded values in USP that ranged from 85% to 115% using 10 
canisters. Moreover, the results of dose uniformity per the whole 
canister showed that (99%±0.45) and (105%±0.11) for SS and 
niosomal SS, respectively which meet the compendia requirements 
that ranged from 85% to 115% using 10 canisters. 
 
 
Fig. 3: Malvern mastersizer report of the particle size of REV SS niosomes in MDIs 
Note: D(4,N), D(3,N), D(2,N), D(1,N) are the equivalent derived diameter at 90, 80, 50 and 10% cumulative volume 
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Table 3: Pharmacopeial specifications of the prepared aerosols 
Test Salbutamol sulphate aerosol Niosomal salbutamol sulphate aerosol  
Limit  Pharmacopeial specifications 
Leakage test (mg/year) 425±1.89 472±0.56 Comply 
Weight variations (g) 23.42±0.24 20.65±0.33 Comply 
Weight per puff (mg) 83±0.31 80±0.27 Comply 
Number of puffs/can (del/can) 190±0.53 215±0.61 Comply 
Dose uniformity/puff% 115±0.19 95±0.55 Comply 
Dose uniformity/can% 99±0.45 105±0.11 Comply 
Note: All values were represented as mean±SD (n=3), P<0.05 
 
CONCLUSION 
The findings of this investigation showed that; niosomes prepared by 
REV method entrapped high amount of water soluble SS. REV SS 
niosomes can be formulated as MDI with physical properties met the 
USP requirements, and so it could be delivered to lung as targeting 
delivery systems, which maximize the delivery of the drug while 
minimize its clearance, that guarantees controlled drug delivery with 
reduced number of dosing which helps to reduce the side effects. It also 
offers a great opportunity for deposition and retention of water-soluble 
compounds in the lung with great potential to relieve asthma symptoms. 
In this light, our future studies will use the current results in translating 
this technology in clinics after conducting further in vivo investigations. 
Research involving human and animal participants 
This article does not contain any studies with human and animal 
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